IBI Webinar: GLP-1 Medications and the Workforce

GLP-1 medications are now among the largest single-class line items on the employer pharmacy ledger, and benefits leaders are being asked to make consequential coverage decisions before the evidence they need fully exists. IBI's new systematic review synthesizes peer-reviewed clinical trials, employer claims studies, health economics analyses, and benefits industry surveys to give members an honest account of what the research shows, where it falls short, and what it means for coverage and program design.